The global anal cancer market is estimated to be valued at US$ 810.4 million in 2021 and is expected to exhibit a CAGR of 6.3% over the forecast period (2021-2028).
The increasing incidence of anal cancer and sexually transmitted diseases is expected to drive the growth of the global anal cancer market over the forecast period.
For instance, according to data published by the National Cancer Institute Surveillance, Epidemiology, and End Results (SEER) Program, U.S, it is estimated that the rate of new cases of anal cancer has increased from 1.7 per 100,000 persons in 2008 to 1.8 per 100,000 persons in 2018 and is expected to increase following the same trend in near future.
The increasing research and development activities for the development of novel therapeutics for the treatment of anal cancer is expected to drive the market growth over the forecast period.
Key players operating in the market are focusing on research and development activities for treatment of anal cancer, which is expected to drive growth of the global anal cancer market over the forecast period.
For instance, in October 2016, Dana-Farber Cancer Institute, Massachusetts and Merck Sharp & Dohme Corp., a U.S. based pharmaceutical company initiated a phase II clinical trial study for assessing the potential use of Pembrolizumab, a monoclonal antibody drug manufactured by Merck Sharp & Dohme Corp. for treatment of advanced anal cancer. This phase II clinical study is expected to be completed by March 2023.
Anal Cancer Market Report Snapshots
Joining thousands of companies around the world committed to making the Excellent Business Solutions.
View All Our Clients